Johnson & Johnson is nearing a deal to acquire U.S. cancer drugmaker Pharmacyclics.» Read More
CNBC's Meg Tirrell reports where the money raised in the ALS ice bucket challenge went.
Outbreaks of measles and whooping cough in California have rekindled debates over "anti-vaxxers"——here is a map of where they live.
Pfizer is buying Hospira, which calls itself the world's leading provider of injectable drugs and infusion technologies. So what the heck are they?
AstraZeneca reported a loss for the fourth quarter of 2014, but stressed that it was on track to return to growth by 2017.
Yaron Werber, Citigroup, shares his basket approach to investing in biotech stocks Gilead, Celgene and others.
Discounts on Gilead's hepatitis C drugs this year will be 46 percent, way more than investors and analysts expected.
Gilead Sciences posted strong sales of its hepatitis C drugs Harvoni and Sovaldi, sending its net profit up more than four-fold for the quarter.
Shares of GlaxoSmithKline jumped on Wednesday, despite the company posting a 3 percent fall in full-year revenue.
Merck said the U.S. FDA intends to rescind its "breakthrough" designation for its experimental combination treatment for hep C.
Sen. Rand Paul clarified his views on vaccinations following an interview with CNBC in which he linked childhood vaccines with disorders.
A leading group of physicians is warning that high prices of specialty drugs is creating barriers to care for patients.
Public health officials implored parents to vaccinate their children against the measles in a Tuesday Congressional hearing.
Dr. Gail Shust, an infectious disease specialist, tells CNBC, "It really is not just a personal choice but a public health issue."
Sanofi launched an inhalable insulin in the U.S. in a potential boost for its flagging diabetes drug sales and for patient quality of life.
A trial of an Ebola drug has been halted because of a sharp decline in patients with the disease in Liberia, the NYT reports.
CNBC's Meg Tirrell, has the latest details on the White House summit with medical researchers.
John Schroer, Allianz portfolio manager, shares his thoughts on precision medicine, and reveals his top biotech stock picks.
Brent Saunders, Actavis CEO, discusses how Actavis is leading the way in growth pharma and talks about its M&A strategy.
Robert Hugin, Celgene chairman & CEO, discusses his company's efforts to fight cancer and discusses promising drugs in the pipeline.
President Obama will dedicate $215 million in his budget request to a program that will target the underlying cause of disease.
Get the best of CNBC in your inbox